XML 14 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Income and Comprehensive Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenues $ 50,746 $ 41,927
Cost of products sold 38,001 30,457
Gross profit 12,745 11,470
Operating expenses:    
Research and development 2,404 1,756
Selling, general and administrative 6,942 5,651
Total operating expenses 9,346 7,407
Operating income 3,399 4,063
Other (expense) income:    
Interest and financing expense 1,032 520
Miscellaneous income (79) (64)
Total other (expense) income 953 456
Income before income taxes 2,446 3,607
Income tax provision 567 703
Net income 1,879 2,904
Net income attributable to non-controlling interest 14 13
Net income attributable to Ultralife Corporation 1,865 2,891
Other comprehensive loss:    
Foreign currency translation adjustments 311 (232)
Comprehensive income attributable to Ultralife Corporation $ 2,176 $ 2,659
Net income per share attributable to Ultralife common stockholders – basic (in dollars per share) $ 0.02 $ 0.08
Net income per share attributable to Ultralife common stockholders – diluted (in dollars per share) $ 0.02 $ 0.08
Weighted average shares outstanding – basic (in shares) 16,633 16,396
Potential common shares (in shares) 47 122
Weighted average shares outstanding - diluted (in shares) 16,680 16,518